A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Public ClinicalTrials.gov record NCT07129252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
Study identification
- NCT ID
- NCT07129252
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2025 (Actual)
- Primary completion
- Aug 2027 (Estimated)
- Completion
- Aug 2029 (Estimated)
- Last update posted
- Oct 13, 2026
2025 – 2029
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Crinetics Study Site | Phoenix | Arizona | 85054 | — |
| Crinetics Study Site | Duarte | California | 91010 | — |
| Crinetics Study Site | Newport Beach | California | 92663 | — |
| Crinetics Study Site | Orange | California | 92868 | — |
| Crinetics Study Site | San Francisco | California | 60637 | — |
| Crinetics Study Site | Aurora | Colorado | 80045 | — |
| Crinetics Study Site | Denver | Colorado | 80218 | — |
| Crinetics Study Site | New Haven | Connecticut | 48201 | — |
| Crinetics Study Site | Atlanta | Georgia | 30322 | — |
| Crinetics Study Site | Lexington | Kentucky | 40536 | — |
| Crinetics Study Site | Metairie | Louisiana | 70006 | — |
| Crinetics Study Site | Detroit | Michigan | 48201 | — |
| Crinetics Study Site | Grand Rapids | Michigan | 49503 | — |
| Crinetics Study Site | Rochester | Minnesota | 53905 | — |
| Crinetics Study Site | New York | New York | 10016 | — |
| Crinetics Study Site | Philadelphia | Pennsylvania | 19104 | — |
| Crinetics Study Site | Philadelphia | Pennsylvania | 19111 | — |
| Crinetics Study Site | Austin | Texas | 78758 | — |
| Crinetics Study Site | Houston | Texas | 70030 | — |
| Crinetics Study Site | Irving | Texas | 75039 | — |
| Crinetics Study Site | Salt Lake City | Utah | 84112 | — |
| Crinetics Study Site | Charlottesville | Virginia | 22908 | — |
| Crinetics Study Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07129252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2026 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07129252 live on ClinicalTrials.gov.